Coherus Oncology, Inc. (CHRS) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $13.81M | +58.3% |
| 2024 | $8.73M | -94.5% |
| 2023 | $158.99M | +126.9% |
| 2022 | $70.08M | +21.7% |
| 2021 | $57.59M | +52.9% |
| 2020 | $37.67M | +120.6% |
| 2019 | $17.08M | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $13.81M | +58.3% |
| 2024 | $8.73M | -94.5% |
| 2023 | $158.99M | +126.9% |
| 2022 | $70.08M | +21.7% |
| 2021 | $57.59M | +52.9% |
| 2020 | $37.67M | +120.6% |
| 2019 | $17.08M | — |